Predicting the outcome of immunotherapy in oesophagogastric cancer
Research type
Research Study
Full title
Predicting the Outcome of ChemoImmunotherapy in Cancer of the Oesophagus - PRECISE
IRAS ID
317343
Contact name
Mark Middleton
Contact email
Sponsor organisation
University of Oxford
Clinicaltrials.gov Identifier
194443, IRAS number for related clinical trial
Duration of Study in the UK
5 years, 11 months, 2 days
Research summary
Starting in 2016 we conducted a study of immunotherapy in the treatment of oesophagogastric cancer. The clinical element of the trial is drawing t oa close, and we plan to conclude the study in the third quarter of 2022. As part of the study we collected tumour and blood samples from participants to study the biological effects of treatment. This project seeks to continue laboratory based research on these samples after the trial has finished, and link our observations with the clinical data. The aim is to help us predict who should (or should not) have immunotherapy as part of their cancer treatment.
REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
22/NE/0183
Date of REC Opinion
8 Sep 2022
REC opinion
Favourable Opinion